Peringatan Keamanan

The oral LD50 of PEG 3350 in rats is 22000 mg/kg.L11857

There is limited clinical information on the overdose of polyethylene glycols. Based on the pharmacological action of the compound, severe diarrhea may be suspected. Overdose of polyethylene glycols should be responded with symptomatic and supportive care.

Polyethylene glycol

DB09287

small molecule approved vet_approved

Deskripsi

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage.A190975,A190978 PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule.A190975 Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights.A190978 The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation.L11812 PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.L6421

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.A18713

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Following a two-day split-dosing regimen of an oral suspension containing 140 grams of PEG 3350 in healthy subjects, the mean half life was 4.1 hours.[L6421]
Volume Distribusi Following a two-day split-dosing regimen of an oral suspension containing 140 grams of PEG 3350 in healthy subjects, the mean volume of distribution was 48,481 L.[L6421]
Klirens (Clearance) There is limited information on the clearance rate of polyethylene glycols.

Absorpsi

Following a two-day split-dosing regimen of an oral suspension containing 140 grams of PEG 3350 in healthy subjects, the mean Cmax was 2.7 mcg/mL and the mean Tmax was 3 hours.L6421 Typically, polyethylene glycols with a high molecular weight are poorly absorbed from the gastrointestinal tract following oral administration.A190975,A190978

Metabolisme

Polyethylene glycol is a metabolically inert laxative that does not undergo intestinal enzymatic degradation or bacterial metabolism.A18713,A177092

Rute Eliminasi

Following administration of an oral suspension containing 140 grams of PEG 3350 in healthy subjects, up to 85% to 99% of the compound was excreted in the feces.L6421

Interaksi Makanan

3 Data
  • 1. Avoid alcohol. Withdrawing from alcohol increases the risk of seizures, which is also caused by the drug.
  • 2. Avoid milk and dairy products.
  • 3. Avoid solid foods. Consume only clear liquids from the start of drug treatment until after the colonoscopy.

Interaksi Obat

447 Data
Peginterferon alfa-2a The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2a.
Pegfilgrastim The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegfilgrastim.
Peginterferon alfa-2b The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2b.
Pegaspargase The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegaspargase.
Pegademase The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegademase.
Pegvisomant The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegvisomant.
Heptaethylene glycol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Heptaethylene glycol.
Pegaptanib The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegaptanib.
Egaptivon pegol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Egaptivon pegol.
PEG-uricase The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with PEG-uricase.
Peginterferon alfacon-1 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfacon-1.
GlycoPEG-GCSF The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with GlycoPEG-GCSF.
Pegnivacogin The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegnivacogin.
Pegpleranib The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegpleranib.
Pegsunercept The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegsunercept.
Polidocanol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Polidocanol.
Peginesatide The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginesatide.
Certolizumab pegol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Certolizumab pegol.
Methoxy polyethylene glycol-epoetin beta The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.
Peginterferon beta-1a The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon beta-1a.
Pegloticase The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegloticase.
Antihemophilic factor (recombinant), PEGylated The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Polyethylene glycol.
Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Polyethylene glycol.
Eptacog alfa pegol (activated) The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Polyethylene glycol.
Olaptesed Pegol The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Polyethylene glycol.
Abicipar Pegol The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polyethylene glycol.
Lexaptepid pegol The therapeutic efficacy of Lexaptepid pegol can be decreased when used in combination with Polyethylene glycol.
Cepeginterferon alfa-2B The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Polyethylene glycol.
Pegvaliase The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Polyethylene glycol.
Pegamotecan The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Polyethylene glycol.
Lipegfilgrastim The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Polyethylene glycol.
Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Polyethylene glycol.
Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Polyethylene glycol.
Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Polyethylene glycol.
Digoxin The serum concentration of Digoxin can be decreased when it is combined with Polyethylene glycol.
Metildigoxin The serum concentration of Metildigoxin can be decreased when it is combined with Polyethylene glycol.
Acetyldigoxin The serum concentration of Acetyldigoxin can be decreased when it is combined with Polyethylene glycol.
Trospium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Trospium.
Oxyphenonium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxyphenonium.
Benzatropine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Benzatropine.
Ziprasidone The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ziprasidone.
Disopyramide The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Disopyramide.
Ipratropium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ipratropium.
Metixene The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Metixene.
Buclizine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Buclizine.
Doxylamine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Doxylamine.
Trihexyphenidyl The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Trihexyphenidyl.
Oxyphencyclimine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxyphencyclimine.
Procyclidine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Procyclidine.
Profenamine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Profenamine.
Promazine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Promazine.
Hyoscyamine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hyoscyamine.
Cyproheptadine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cyproheptadine.
Methscopolamine bromide The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methscopolamine bromide.
Gallamine triethiodide The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Gallamine triethiodide.
Darifenacin The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Darifenacin.
Tridihexethyl The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tridihexethyl.
Triflupromazine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Triflupromazine.
Anisotropine methylbromide The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Anisotropine methylbromide.
Nortriptyline The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nortriptyline.
Amoxapine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Amoxapine.
Atropine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Atropine.
Pirenzepine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pirenzepine.
Paroxetine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Paroxetine.
Homatropine methylbromide The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Homatropine methylbromide.
Rocuronium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Rocuronium.
Scopolamine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Scopolamine.
Benzquinamide The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Benzquinamide.
Clidinium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Clidinium.
Propiomazine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Propiomazine.
Propantheline The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Propantheline.
Dicyclomine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dicyclomine.
Biperiden The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Biperiden.
Brompheniramine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Brompheniramine.
Cocaine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cocaine.
Maprotiline The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Maprotiline.
Methantheline The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methantheline.
Cycrimine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cycrimine.
Glycopyrronium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Glycopyrronium.
Tolterodine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tolterodine.
Oxybutynin The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxybutynin.
Promethazine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Promethazine.
Diphenhydramine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Diphenhydramine.
Doxacurium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Doxacurium.
Flavoxate The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Flavoxate.
Desipramine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Desipramine.
Orphenadrine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Orphenadrine.
Escitalopram The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Escitalopram.
Mivacurium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Mivacurium.
Diphenidol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Diphenidol.
Aripiprazole The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aripiprazole.
Chlorprothixene The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Chlorprothixene.
Metocurine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Metocurine.
Pancuronium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pancuronium.
Pipecuronium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pipecuronium.
Methotrimeprazine The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methotrimeprazine.
Tiotropium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tiotropium.
Solifenacin The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Solifenacin.
Isopropamide The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Isopropamide.
Rapacuronium The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Rapacuronium.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 10703152
    Hammer HF, Hammer J, Gasche C: Polyethylene glycol (Macrogol)--an overview of its use in diagnosis and therapy of gastrointestinal diseases. Wien Klin Wochenschr. 2000 Jan 28;112(2):53-60.
  • PMID: 27871178
    Minguez M, Lopez Higueras A, Judez J: Use of polyethylene glycol in functional constipation and fecal impaction. Rev Esp Enferm Dig. 2016 Dec;108(12):790-806. doi: 10.17235/reed.2016.4571/2016.
  • PMID: 28147222
    Fordtran JS, Hofmann AF: Seventy Years of Polyethylene Glycols in Gastroenterology: The Journey of PEG 4000 and 3350 From Nonabsorbable Marker to Colonoscopy Preparation to Osmotic Laxative. Gastroenterology. 2017 Mar;152(4):675-680. doi: 10.1053/j.gastro.2017.01.027. Epub 2017 Jan 29.
  • PMID: 23449608
    Portalatin M, Winstead N: Medical management of constipation. Clin Colon Rectal Surg. 2012 Mar;25(1):12-9. doi: 10.1055/s-0032-1301754.

Contoh Produk & Brand

Produk: 289 • International brands: 3
Produk
  • Aquasite Dps
    Solution / drops • - • Ophthalmic • Canada • OTC • Approved
  • Basic Care Clearlax
    Powder, for solution • 17 g/17g • Oral • US • Generic • OTC • Approved
  • Basic Care Clearlax
    Powder, for solution • 17 g/17g • Oral • US • Generic • OTC • Approved
  • Basic Care Clearlax
    Powder, for solution • 17 g/17g • Oral • US • Generic • OTC • Approved
  • Berkley and Jensen Clearlax
    Powder, for solution • 17 g/17g • Oral • US • Generic • OTC • Approved
  • BET-R-Prep
    Powder, for solution • 17 g/17g • Oral • US • OTC • Approved
  • Bi-peglyte
    Kit; Powder, for solution; Tablet, delayed release • - • Oral • Canada • Approved
  • Care One Clearlax
    Powder, for solution • 17 g/17g • Oral • US • Generic • OTC • Approved
Menampilkan 8 dari 289 produk.
International Brands
  • Fortrans
  • GlycoLax
  • TriLyte

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul